Skip to main content
Top
Published in: Hepatology International 2/2024

13-10-2023 | Hepatitis | Original Article

New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32

Authors: Tae Hyung Kim, Hyung Joon Yim, Young Kul Jung, Do Seon Song, Eileen L. Yoon, Hee Yeon Kim, Seong Hee Kang, Young Chang, Jeong-Ju Yoo, Baek Gyu Jun, Sung Won Lee, Jung Gil Park, Ji Won Park, Sung-Eun Kim, Tae Yeob Kim, Soung Won Jeong, Ki Tae Suk, Moon Young Kim, Sang Gyune Kim, Won Kim, Jae Young Jang, Jin Mo Yang, Dong Joon Kim, The Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Background & aims

Few studies have investigated the prognosis of patients with non-severe alcoholic hepatitis (Non-SAH). The study aimed to develop a new prognostic model for patients with especially Non-SAH.

Methods

We extracted 316 hospitalized patients with alcoholic cirrhosis without severe alcoholic hepatitis, defined as Maddrey’s discriminant function score lower than 32, from the retrospective Korean Acute-on-Chronic Liver Failure (KACLiF) cohort to develop a new prognostic model (training set), and validated it in 419 patients from the prospective KACLiF cohort (validation set). Prognostic factors for death and liver transplantation were analyzed to construct a prognostic model.

Results

Twenty-one and 24 patients died within 6 months in both sets, respectively. In the training set, the highest area under the curve (AUC) of conventional prognostic models was 0.765, 0.732, and 0.684 for 1-, 3-, and 6-month mortality, respectively. Refractory ascites, vasopressor use, and hyponatremia were independently associated with mortality of cirrhotic patients with Non-SAH. The new model consisted of four variables: past deterioration, neutrophil proportion > 70%, Na < 128 mmol/L, and vasopressor use. It showed the highest accuracy for short-term mortality in the training and validation sets (0.803 and 0.786; 0.797 and 0.776; and 0.789 and 0.721 for 1-, 3-, and 6-month mortality, respectively).

Conclusion

There is a group of patients with high risk among those classified as Non-SAH. The new model will help stratifying cirrhotic patients with Non-SAH more accurately in terms of prognosis. The patients with high Non-SAH score need to monitor closely and might be considered for preemptive liver transplantation.

Trial regestration

ClinicalTrials.gov identifier: NCT02650011.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wong RJ, Singal AK. Trends in lliver ddisease eetiology aamong aadults aawaiting lliver ttransplantationliver disease etiology among adults awaiting liver transplantation in the United States, 2014–2019. JAMA Netw Open. 2020;3(2): e1920294CrossRefPubMed Wong RJ, Singal AK. Trends in lliver ddisease eetiology aamong aadults aawaiting lliver ttransplantationliver disease etiology among adults awaiting liver transplantation in the United States, 2014–2019. JAMA Netw Open. 2020;3(2): e1920294CrossRefPubMed
2.
go back to reference European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154–181CrossRef European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154–181CrossRef
3.
go back to reference Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:249–257CrossRefPubMed Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:249–257CrossRefPubMed
4.
go back to reference Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatol. 2017;66:1464–1473CrossRef Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatol. 2017;66:1464–1473CrossRef
5.
go back to reference Shin J, Yu JH, Jin Y-J, et al. Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding. Clin Mol Hepatol. 2020;26:540–553CrossRefPubMedPubMedCentral Shin J, Yu JH, Jin Y-J, et al. Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding. Clin Mol Hepatol. 2020;26:540–553CrossRefPubMedPubMedCentral
6.
go back to reference Kim JH, Kim SE, Song DS, et al. Platelet-to-white blood cell ratio is associated with adverse outcomes in cirrhotic patients with acute deterioration. J Clin Med. 2022;11:2463CrossRefPubMedPubMedCentral Kim JH, Kim SE, Song DS, et al. Platelet-to-white blood cell ratio is associated with adverse outcomes in cirrhotic patients with acute deterioration. J Clin Med. 2022;11:2463CrossRefPubMedPubMedCentral
7.
go back to reference Yoon EL, Kim TY, Song DS, et al. The impact of previous acute decompensation on the long-term prognosis of alcoholic hepatitis in cirrhotic patients. J Clin Med. 2019;8:1600CrossRefPubMedPubMedCentral Yoon EL, Kim TY, Song DS, et al. The impact of previous acute decompensation on the long-term prognosis of alcoholic hepatitis in cirrhotic patients. J Clin Med. 2019;8:1600CrossRefPubMedPubMedCentral
8.
go back to reference Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther. 2022;55:83–96CrossRefPubMed Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther. 2022;55:83–96CrossRefPubMed
9.
go back to reference Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216–254CrossRef Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216–254CrossRef
10.
go back to reference Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655CrossRefPubMed Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655CrossRefPubMed
11.
go back to reference Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353–390CrossRefPubMed Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353–390CrossRefPubMed
13.
go back to reference Degré D, Stauber RE, Englebert G, et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32. J Hepatol. 2020;72:636–642CrossRefPubMed Degré D, Stauber RE, Englebert G, et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32. J Hepatol. 2020;72:636–642CrossRefPubMed
15.
go back to reference Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018;24:230–277CrossRef Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018;24:230–277CrossRef
16.
go back to reference Kim TH, Ku DH, Um SH, et al. How can we improve the performance of model for end-stage liver disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment? J Gastroenterol Hepatol. 2018;33:1641–1648CrossRef Kim TH, Ku DH, Um SH, et al. How can we improve the performance of model for end-stage liver disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment? J Gastroenterol Hepatol. 2018;33:1641–1648CrossRef
17.
go back to reference Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the Modern Era. Gastroenterology. 2021;161:1887–1895CrossRefPubMed Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the Modern Era. Gastroenterology. 2021;161:1887–1895CrossRefPubMed
18.
go back to reference Cárdenas A, Solà E, Rodríguez E, et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANonIC study. Crit Care. 2014;18:700CrossRefPubMedPubMedCentral Cárdenas A, Solà E, Rodríguez E, et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANonIC study. Crit Care. 2014;18:700CrossRefPubMedPubMedCentral
19.
go back to reference Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398:1359–1376CrossRefPubMed Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398:1359–1376CrossRefPubMed
20.
go back to reference Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatol. 2016;64:1249–1264CrossRef Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatol. 2016;64:1249–1264CrossRef
21.
go back to reference Forrest EH, Storey N, Sinha R, et al. Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:442–453CrossRefPubMed Forrest EH, Storey N, Sinha R, et al. Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:442–453CrossRefPubMed
22.
go back to reference Chen L, Lou Y, Chen Y, Yang J. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure. Int J Clin Pract. 2014;68:1034–1040CrossRefPubMed Chen L, Lou Y, Chen Y, Yang J. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure. Int J Clin Pract. 2014;68:1034–1040CrossRefPubMed
23.
go back to reference Cai YJ, Dong JJ, Dong JZ, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther. 2017;45:1413–1426CrossRefPubMed Cai YJ, Dong JJ, Dong JZ, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther. 2017;45:1413–1426CrossRefPubMed
24.
go back to reference Sun J, Guo H, Yu X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure. BMC Gastroenterol. 2021;21:422CrossRefPubMedPubMedCentral Sun J, Guo H, Yu X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure. BMC Gastroenterol. 2021;21:422CrossRefPubMedPubMedCentral
25.
go back to reference Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73:842–854CrossRefPubMed Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73:842–854CrossRefPubMed
Metadata
Title
New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32
Authors
Tae Hyung Kim
Hyung Joon Yim
Young Kul Jung
Do Seon Song
Eileen L. Yoon
Hee Yeon Kim
Seong Hee Kang
Young Chang
Jeong-Ju Yoo
Baek Gyu Jun
Sung Won Lee
Jung Gil Park
Ji Won Park
Sung-Eun Kim
Tae Yeob Kim
Soung Won Jeong
Ki Tae Suk
Moon Young Kim
Sang Gyune Kim
Won Kim
Jae Young Jang
Jin Mo Yang
Dong Joon Kim
The Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group
Publication date
13-10-2023
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10582-1

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.